The purpose of this website is to provide educational information for practitioners on biologic materials, orthopedic protocols, regulatory considerations, and general best practices. This content is intended for professional education only and does not constitute medical advice or approved treatment recommendations.

Biologic therapies in lung diseases focus on reducing inflammation, repairing damaged lung tissue, and improving oxygen exchange. By enhancing mitochondrial function and cellular regeneration, these treatments target chronic and progressive respiratory conditions.
Chronic Obstructive Pulmonary Disease (COPD): Chronic inflammation causing airflow limitation.
Pulmonary Fibrosis: Scarring of lung tissue leading to reduced elasticity.
Asthma: Chronic airway inflammation resulting in breathing difficulties.
Acute Respiratory Distress Syndrome (ARDS): Severe inflammation and fluid buildup in the lungs.
Lung Damage Post-COVID-19: Residual lung scarring and inflammation from COVID-19.
Stem cells restore lung tissue by reducing inflammation and promoting repair of alveoli (air sacs). Their exosomes improve mitochondrial function, which is crucial for energy production and efficient oxygen exchange.
Mesenchymal Stem Cell (MSC) Therapy: High-quality MSCs repair damaged lung tissues and modulate inflammation.
Exosome Therapy: Reduces inflammatory cytokines and enhances tissue regeneration.
IV Infusion of Biologics: Delivers systemic support for widespread lung conditions.
Patient Selection:
Ideal Candidates: Individuals with chronic respiratory diseases or post-viral lung damage.
Contraindications: Active respiratory infections or advanced lung failure requiring immediate mechanical support.
Preparation:
Pulmonary Function Tests (PFTs): Assess baseline lung capacity and function.
Imaging: Chest X-rays or CT scans to evaluate lung structure.
Administration:
IV Infusion: Delivers biologics to modulate systemic and localized lung inflammation.
Nebulized Biologics (Experimental): Inhalation therapy for direct lung delivery.
Post-Treatment Care:
Recommend pulmonary rehabilitation and breathing exercises.
Regular follow-ups to monitor lung function improvement.
MSC Therapy for Pulmonary Fibrosis: Highlights stem cell efficacy in reducing scarring and inflammation. Read study
Exosomes in Respiratory Diseases: Discusses the therapeutic role of exosomes in lung repair. Read study


About
Our mission is to equip practitioners with essential knowledge on biologics, covering protocols, regulatory guidelines, and foundational insights. This site serves as a trusted resource for navigating the evolving landscape of stem cell applications in clinical practice.
Disclaimer
The information on this website is provided solely for informational purposes and has not been reviewed or approved by the FDA or any other regulatory authority. It does not constitute medical advice, diagnosis, treatment, or any guarantees of medical outcomes and should not be used as a substitute for formal medical education and training, nor as a substitute for consultation with qualified healthcare professionals. Similarly, the content does not provide legal advice or guidance on regulatory compliance and should not replace consultations with qualified legal professionals.
DiscoverBiologics.com makes no representations or warranties, express or implied, regarding the accuracy, reliability, or applicability of the information provided to individual health circumstances or the legal use and adoption of biological products by clinics or providers.
By accessing this website, you agree to the terms and conditions outlined herein and accept full responsibility for compliance and clinical decisions made within your practice. You also acknowledge that you have been encouraged to review the disclaimer page and understand that any reliance on the information provided is voluntary and at your own risk and sole discretion.
2025 © All Rights Reserved. DiscoverBiologics.com